Core Viewpoint - InnovAge Holding Corp. has announced a joint venture with Tampa General Hospital to enhance community-based care options for seniors in the Tampa Bay area, focusing on improving access to quality care for clinically frail and underserved seniors [1][2]. Company Overview - InnovAge is a leader in senior care through the Program of All-Inclusive Care for the Elderly (PACE), aiming to help seniors live independently at home while receiving necessary healthcare and support [1][5]. - As of March 31, 2025, InnovAge served approximately 7,530 participants across 20 centers in six states [6]. Joint Venture Details - The joint venture aims to expand innovative community-based care options and improve access to quality care for seniors in Hillsborough, Pasco, and Hernando counties [2]. - The InnovAge Florida PACE center in Tampa has a 35,000-square-foot facility capable of serving around 1,300 seniors, offering a range of services including primary and specialty medical care, dental services, rehabilitation therapies, and social activities [4]. Tampa General Hospital Overview - Tampa General Hospital is recognized as the 1 hospital in the Tampa Bay region for the 10th consecutive year and is noted for its excellence in geriatrics [3]. - The hospital is a not-for-profit academic health system with 1,529 beds and is the only center for Level 1 trauma and comprehensive burn care in the region [7]. - In fiscal year 2023, Tampa General provided a net community benefit of approximately $301.8 million, supporting underinsured patients and community health organizations [8].

Core Insights - Foresight Autonomous Holdings Ltd. reported financial results for Q2 and the first half of 2025, highlighting progress in commercial agreements and technological advancements in 3D perception systems [1][4][6]. Second Quarter Corporate Highlights - Revenues for Q2 2025 were $128,000, a slight increase from $123,000 in Q2 2024, primarily driven by agreements with Elbit Systems and successful testing with Software République [6]. - The company signed a $12 million commercialization agreement with Zhejiang StreamRail for urban rail transit integration, with expected deployment in 2026 [7]. - A collaboration with a Tier-One automotive supplier aims to enhance bus safety using Foresight's technology, with proof-of-concept testing ongoing in H2 2025 [7]. First Half 2025 Corporate Highlights - Total revenues for the first half of 2025 reached $240,000, compared to $224,000 in the same period of 2024 [9]. - Research and development expenses decreased by 2.2% to $4,426,000, while sales and marketing expenses increased by 9.2% to $629,000 [9]. - General and administrative expenses rose by 11.6% to $1,296,000, mainly due to increased share-based compensation [9]. Financial Performance - GAAP net loss for Q2 2025 was $2,815,000, improving from a loss of $3,172,000 in Q2 2024 [9]. - Non-GAAP net loss for Q2 2025 was $2,598,000, compared to $3,030,000 in Q2 2024 [10]. - For the first half of 2025, GAAP net loss was $6,095,000, compared to $4,708,000 in the first half of 2024 [10]. Balance Sheet Highlights - As of June 30, 2025, cash and cash equivalents totaled $6,392,000, down from $7,182,000 at the end of 2024 [18]. - Total equity decreased by 16.4% to $5,625,000, primarily due to the net loss for the period [18]. Technological Developments - Foresight enhanced its perception systems by integrating NVIDIA Jetson Orin platforms, significantly improving AI processing capabilities for automotive and drone applications [7]. - Eye-Net Mobile made significant strides in V2X safety, completing a paid proof-of-concept with a major European OEM and achieving successful trial results in France [5].

Reference is made to IDEX Biometrics ASA’s disclosure on 21 July 2025 of a private placement of 9,090,909 shares at NOK 3.30 per share. IDEX discloses the following information on behalf of a major shareholder and primary insider. In connection with the private placement, the manager of the private placement, IDEX Biometrics and Mr. Storbråten entered into a share lending agreement. Mr. Storbråten has lent 4,359,315 shares, in connection with the settlement of Tranche 2. The shares have been lent, not sold ...

NEW YORK, Aug. 15, 2025 (GLOBE NEWSWIRE) -- CLEAR (NYSE: YOU), an official TSA PreCheck® enrollment provider, is making it easier and more affordable for travelers to get through security faster. As part of the Transportation Security Administration’s (TSA) Families on the Fly campaign, CLEAR is offering a limited-time Buy One, Get One $15 Off promotion for TSA PreCheck® enrollment when two family members sign up together. From now through October 31, 2025, new applicants who enroll together at the same enr ...

Company Overview - YD Biopharma Limited is a clinical-stage biopharmaceutical company focused on cancer prevention medical diagnostics and the development of exosome-based therapeutics aimed at addressing diseases with high unmet medical needs [6] - The company has established itself as a recognized supplier of clinical trial drugs and is also developing post-market auxiliary products [6] Business Combination Details - Breeze Holdings Acquisition Corp. announced the approval of its business combination with YD Biopharma, with stockholders voting overwhelmingly in favor (3,127,474 shares for, 1,000 against, and 21 abstentions) [3] - The combined entity will operate under the name YD Bio Limited and is expected to trade on Nasdaq with the ticker symbol "YDES" [4] - The transaction is anticipated to close within the next two weeks, pending customary closing conditions [4] Advisors Involved - Legal and financial advisors for the transaction include ArentFox Schiff LLP for YD Biopharma, I-Bankers Securities, Inc. for Breeze, and Woolery & Co. PLLC for Breeze [5]

League commissioners nationwide can secure their spot early and score perks like draft kits, food and drink specials, and exclusive kickback cards DALLAS, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Twin Peaks Restaurant, the ultimate sports lodge, is a point up on fantasy football this season with the launch of its first nationwide online draft party table reservation system in addition to exclusive offers for league commissioners. Through Sept. 4, fans can book tables at their local Twin Peaks and score exclusive p ...

Core Viewpoint - HF Sinclair Corporation has announced the pricing terms for its cash tender offer to purchase all outstanding notes, with all other terms remaining unchanged as per the Offer to Purchase dated August 11, 2025 [1][2]. Tender Offer Details - The consideration for each series of notes accepted for purchase is determined by a fixed spread over the yield based on U.S. Treasury Securities [2]. - The tender offer will remain open until 5:00 p.m. New York City time on August 15, 2025, unless extended or terminated [6]. - Settlement for all validly tendered notes is expected on August 20, 2025 [7]. Notes Information - The tender offer includes: - 5.875% Senior Notes due 2026 with an aggregate principal amount of $153,585,000, a reference yield of 4.226%, and a tender offer consideration of $1,004.12 [3]. - 6.375% Senior Notes due 2027 with an aggregate principal amount of $249,875,000, a reference yield of 4.035%, and a tender offer consideration of $1,011.63 [3]. Company Overview - HF Sinclair Corporation is an independent energy company that produces and markets high-value light products, including gasoline, diesel fuel, and renewable diesel [10]. - The company operates refineries in multiple states and provides transportation, storage, and throughput services to the petroleum industry [10]. - HF Sinclair markets its refined products primarily in the Southwest U.S. and has a significant presence in the renewable diesel market [10].

Core Insights - Tonmya is the first FDA-approved therapy for fibromyalgia in over 15 years, representing a significant advancement for the treatment of this chronic pain condition affecting over 10 million adults in the U.S. [1][2] - The approval of Tonmya was based on two pivotal Phase 3 clinical trials that demonstrated its efficacy in significantly reducing fibromyalgia pain compared to placebo [2][10] - Tonmya is expected to be commercially available in the fourth quarter of 2025 [1][6] Company Overview - Tonix Pharmaceuticals Holding Corp. is a fully-integrated biotechnology company focused on developing treatments for central nervous system disorders, immunology, immuno-oncology, and infectious diseases [12][13] - The company has a proprietary formulation for Tonmya, which is a sublingual tablet designed for rapid absorption and reduced production of long half-life metabolites [9] Industry Context - Fibromyalgia is a chronic pain disorder that affects an estimated 10 million adults in the U.S., with approximately 80% being women. It is characterized by chronic widespread pain, fatigue, and sleep disturbances [8] - The chronic pain associated with fibromyalgia significantly disrupts patients' daily lives and is often inadequately managed due to a lack of effective treatment options [4][8]

Core Insights - Toll Brothers, Inc. announced the grand opening of seven model homes at The Station, a new luxury home community in Sunnyvale, California, featuring townhomes and condominiums near major tech employers [1][4] Group 1: Community Features - The Station offers two collections of luxury homes: Vantage at The Station and Terraces at The Station, with sizes ranging from 962 to over 2,387 square feet, accommodating up to 4 bedrooms and 3 baths [4] - Homes in The Station are priced from the upper $900,000s, indicating a premium market positioning [4] - The community includes amenities such as a clubhouse, children's playground, dog park, walking paths, and expansive lawns, enhancing the living experience [6] Group 2: Customer Experience - Toll Brothers provides a state-of-the-art Design Studio for customers to personalize their homes with a wide array of selections, supported by professional Design Consultants [5] - Move-in ready homes with Designer Appointed Features are available, allowing buyers to move in later this summer or fall [5] Group 3: Educational Opportunities - Residents have access to highly ranked local schools, including Ellis Elementary, Sunnyvale Middle School, and Fremont High School, as well as sought-after private schools [6] Group 4: Company Background - Toll Brothers is a Fortune 500 Company, recognized as the nation's leading builder of luxury homes, with operations in over 60 markets across 24 states [9] - The company has received multiple accolades, including being named one of Fortune magazine's World's Most Admired Companies for over 10 years [10]

Gross Profit Rises 462% to $6.7 Million Net Income from Continuing Operations Improved by $26.6 Million to $23.7 Million Revenue for First Half of 2025 Increased 382% to $22.9 Million, a $18.1 Million Increase from Prior Year Generated $973,606 in Positive Cash Flow from Continuing Operations in First Half of 2025, Marking a Significant Milestone Reaffirms 2025 Guidance for Net Income of ~$1.3 Million on Revenue of Over $45 Million; Projects 2026 Net Income of ~$5.0 Million on Revenue of More than $60 Mil ...